NASDAQ:CLGN - Nasdaq - IL0004960188 - Common Stock - Currency: USD
2.28
-0.9 (-28.3%)
The current stock price of CLGN is 2.28 USD. In the past month the price increased by 6.04%. In the past year, price decreased by -55.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.21 | 330.30B | ||
AMGN | AMGEN INC | 13.9 | 155.11B | ||
GILD | GILEAD SCIENCES INC | 14.07 | 135.48B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.39B | ||
REGN | REGENERON PHARMACEUTICALS | 11.08 | 52.99B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.91B | ||
ARGX | ARGENX SE - ADR | 101.67 | 35.70B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.19B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.3 | 26.59B | ||
NTRA | NATERA INC | N/A | 21.94B | ||
BIIB | BIOGEN INC | 8.29 | 19.22B | ||
UTHR | UNITED THERAPEUTICS CORP | 12.99 | 14.68B |
CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
COLLPLANT BIOTECHNOLOGIES LT
4 Oppenheimer Street, P.O. Box 4132
Rehovot 7670104 IL
CEO: Yehiel Tal
Employees: 57
Phone: 972732325600
The current stock price of CLGN is 2.28 USD. The price decreased by -28.3% in the last trading session.
The exchange symbol of COLLPLANT BIOTECHNOLOGIES LT is CLGN and it is listed on the Nasdaq exchange.
CLGN stock is listed on the Nasdaq exchange.
7 analysts have analysed CLGN and the average price target is 14.28 USD. This implies a price increase of 526.32% is expected in the next year compared to the current price of 2.28. Check the COLLPLANT BIOTECHNOLOGIES LT stock analysts ratings, price target forecast and up-and down grades for more detailed information.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a market capitalization of 26.11M USD. This makes CLGN a Nano Cap stock.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) currently has 57 employees.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) has a resistance level at 2.29. Check the full technical report for a detailed analysis of CLGN support and resistance levels.
The Revenue of COLLPLANT BIOTECHNOLOGIES LT (CLGN) is expected to grow by 601.14% in the next year. Check the estimates tab for more information on the CLGN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CLGN does not pay a dividend.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) will report earnings on 2025-07-16.
COLLPLANT BIOTECHNOLOGIES LT (CLGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.22).
The outstanding short interest for COLLPLANT BIOTECHNOLOGIES LT (CLGN) is 0.02% of its float. Check the ownership tab for more information on the CLGN short interest.
ChartMill assigns a technical rating of 3 / 10 to CLGN. When comparing the yearly performance of all stocks, CLGN is a bad performer in the overall market: 93.81% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to CLGN. CLGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months CLGN reported a non-GAAP Earnings per Share(EPS) of -1.22. The EPS decreased by -144% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -80.58% | ||
ROE | -111.85% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to CLGN. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 92.32% and a revenue growth 601.14% for CLGN